03rd week of 2009 patent applcation highlights part 47 |
Patent application number | Title | Published |
20090018041 | ETHYLENE-PROPYLENE COPOLYMERS SUITABLE FOR THE MODIFICATION OF LUBRICATING OILS AND PROCESS FOR THE PREPARATION THEREOF - Process for the preparation of viscosity index improver (V.I.I.) additives of lubricating oils which comprises a mixing treatment under high shear conditions of a composition comprising: (i) one or more EP(D)M polymers (ii) one or more polyvinylarene/conjugated hydrogenated polydiene/polyvinylarene block copolymers; and (iii) lubricating oil, (ii) being present in a concentration of 1.5 to 20% by weight whereas (iii) is present in a concentration ranging from 1.5 to 45% by weight. | 2009-01-15 |
20090018042 | PROCESS FOR PRODUCING A MULTI-PHASE DETERGENT TABLET - A process for the manufacture of a detergent tablet comprises filling a recess in a first pre-formed body with a gel; adding a second body to the gel; and allowing/causing the gel to solidify. | 2009-01-15 |
20090018043 | PROCESS FOR MAKING A TABLET - A process for making a tablet having at least three layers, the process comprises:
| 2009-01-15 |
20090018044 | AEROSOL CLEANER WITH CORROSION-INHIBITING ACTION - A nanoparticulate colloidal silica can be used as a corrosion inhibitor in aqueous compositions which are stored in aerosol spray cans. In particular, it is possible to formulate spray cleaners for carpets, said cleaners comprising a nanoparticulate colloidal silica as a corrosion inhibitor as being used in a process for cleaning carpets. | 2009-01-15 |
20090018045 | Liquid Washing or Cleaning Composition Comprising Particulate Peracid Bleach - Aqueous, liquid compositions which comprise a surfactant, a bleaching agent and magnesium sulfate, wherein the bleaching agent comprises a particulate peroxocarboxylic acid which may optionally be coated, along with uses therefor are described. | 2009-01-15 |
20090018046 | TREATED OXIDIZING AGENT, DETERGENT COMPOSITION CONTAINING A TREATING OXIDIZING AGENT, AND METHODS FOR PRODUCING - A treated oxidizing agent is provided according to the invention. The treated oxidizing agent includes an oxidizing agent that is solid at room temperature and atmospheric pressure, and a chemical barrier composition provided on the oxidizing agent. The chemical barrier composition includes a hydrocarbon component having about 10 to about 85 carbon atoms, and wherein the chemical barrier composition is provided as a liquid at 25° C. A solid detergent composition is provided including the treated oxidizing agent. Methods for manufacturing are provided. | 2009-01-15 |
20090018047 | FOAMING HAND SPONGE FOR BODILY CLEANSING WITH COLOR CHANGE INDICATOR - A cleansing product suitable for making the cleaning of both inanimate and animate surfaces more fun and effective for children is disclosed. Specifically, the cleansing product is capable of expanding in volume under certain temperature conditions, and in some embodiments, can additionally include a coloring agent, providing a color change to indicate when sufficient cleansing has been performed. | 2009-01-15 |
20090018048 | FOAMING HAND SPONGE WITH COLOR CHANGE INDICATOR - A cleansing product suitable for making the cleaning of both inanimate and animate surfaces more fun and effective for children is disclosed. Specifically, the cleansing product is capable of expanding in volume under certain temperature conditions, and in some embodiments, can additionally include a coloring agent, providing a color change to indicate when sufficient cleansing has been performed. | 2009-01-15 |
20090018049 | BINDING AGENT FOR SOLIDIFICATION MATRIX - Material, composition, and manufacturing method alternatives for a solidification matrix that may be used, for example, in solid cleaning compositions, or other technologies. In at least some embodiments, the solidification matrix includes a binding agent that is formed by the use of MGDA, or a salt or derivative thereof, and water to produce a solid binding agent. In some embodiments, the MGDA and water combines and can solidify to act as a binder material or binding agent dispersed throughout a solid composition that may contain other functional ingredients that provide the desired properties and/or functionality to the solid composition. | 2009-01-15 |
20090018050 | Multi-purpose cleaning compositions and method - Various multi-purpose cleaning compositions and the method for using the multi-purpose cleaning compositions are provided. In one embodiment the present invention, the multi-purpose cleaning composition comprises, by weight, from about 10% to about 90% by weight potassium pyrophosphate and from about 90% to about 10% by weight of at least one Group 1 lauryl sulfate. In another embodiment of the present invention, the multi-purpose cleaning composition includes solvent and comprises from about 1% to about 25% by weight of at least one Group 1 pyrophosphate, from about 1% to about 25% by weight of at least one surfactant, and from about 50% to about 98% by weight of at least one solvent. The multi-purpose cleaning compositions of the present invention can be used on various surfaces for improved cleaning of a variety of stains and soils and while also being safe to use and environmentally benign. | 2009-01-15 |
20090018051 | USES OF (Z)-1-(3-METHYL-BUT-2-ENYLOXY)-HEX-3-ENE - The use of (Z)-1-(3-methylbut-2-enyloxy)hex-3-ene, or a mixture containing (Z)-1-(3-methylbut-2-enyloxy)hex-3-ene, as an agent for providing (a) hair or (b) textile fibres with a fresh-green smell is described. | 2009-01-15 |
20090018052 | Treatment of Diabetes and Related Pathologies - Methods for treating diabetes mellitus and related conditions and symptoms are described. The methods are directed to administering a therapeutically effective amount of a compound. Compounds suitable for the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. Also disclosed are methods directed to concurrently administering a therapeutically effective amount of a compound with other compounds known in the treatment of diabetes mellitus. In one embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of insulin. In another embodiment, a therapeutically effective amount of a compound is administered concurrently with a therapeutically effective amount of a hypoglycemic compound. | 2009-01-15 |
20090018053 | FORMULATIONS FOR AMYLIN AGONIST PEPTIDES - The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient. | 2009-01-15 |
20090018054 | Cholesteryl Ester Transfer Protein Inhibitors - Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A | 2009-01-15 |
20090018055 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS - Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: | 2009-01-15 |
20090018056 | Heteroarylcarbamoylbenzene derivatives - Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): | 2009-01-15 |
20090018057 | OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES - Oil-in-water emulsion comprising a non-steroidal anti-inflammatory drug and a quaternary ammonium halide useful for the prevention and treatment of inflammation in the eye, and process for manufacturing thereof. | 2009-01-15 |
20090018058 | Vitamin D Receptor Modulators - The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating and psoriasis. | 2009-01-15 |
20090018059 | Method for maintaining pluripotency of stem/progenitor cells - The present invention relates to a method for maintaining pluripotency and/or self-renewing characteristics of stem/progenitor cells. The invention also relates to a method for modulating gene expression in a cell. The methods include contacting at least two transcription factors, or a functional fragment thereof, with the promoter region of the nanog gene. One of the at least two transcription factors is selected from the POU- and homeo-domain-containing transcription factors. Another of the at least two transcription factors is selected from the HMG domain-containing transcription factors. The method further comprises allowing the at least two transcription factors to form a complex with a specific binding element within the nanog promoter. The complex thus formed regulates nanog gene expression by mediating transcriptional activation. | 2009-01-15 |
20090018060 | Thymus-specific protein - The invention provides the novel thymus-specific human protein T101, an 84-amino acid polypeptide isolated from the human thymus. The full T101 peptide contains a 33-amino acid signal peptide and a 51-amino acid T101 peptide sequence with both immune stimulatory and inhibitory activities. Also provided are modified peptides and partial T101 peptide sequences. | 2009-01-15 |
20090018061 | Compositions and Methods for Treating Cardiac Conditions - Pharmaceutical polypeptide compositions promote the survival of cardiac cells, recruit cardiac cells to the cardiac area, stimulate the differentiation of cardiac cells, stimulate the proliferation of cardiac cells, and promote the activity of cardiac cells, thereby treating cardiac conditions. Methods of providing these compositions to the cardiac area include catheterization and direct injection. In preferred embodiments, the compositions comprise one of more of the following growth factors: EGF, hFGF, cardiotrophin-1, thrombin, PDGF-BB, amphiregulin, epiregulin, HB-EGF, TGFalpha, betacellulin, heregulin alpha, NRG-1-beta1-HRG-beta1, FGF 9. | 2009-01-15 |
20090018062 | Malignant tumor-inhibiting preparation comprising des a fibrin - A malignant tumor-inhibiting preparation is provided which comprises Des A fibrin and therefore can inhibit the spreading and migration of malignant tumor cells and thereby can inhibit the malignant tumors. | 2009-01-15 |
20090018063 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISORDERS INVOLVING EPITHELIAL CELL APOPTOSIS - The present invention provides therapeutic and prophylactic compositions for use in treating and preventing disorders involved epithelial cell apoptosis, such as gastrointestinal disorders (e.g., inflammatory bowel disease, Crohn's disease or ulcerative colitis) in a subject, such as a human patient. | 2009-01-15 |
20090018064 | REGULATION OF MINERAL AND SKELETAL METABOLISM - A method is disclosed whereby levels of calcium, phosphate and parathyroid hormone are measured in a patient. The patient is treated with a formulation comprising a compound having phosphotonin activity and thereafter measurements are made again. Dosing of the formulation is adjusted based on measurements with measuring, administering and adjusting dosing continually repeated as needed. | 2009-01-15 |
20090018065 | Plant PR-5 proteins as mammalian therapeutic agents - The Proteins of the PR-5 family having a lectin-like P barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like P barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like β barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like β barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals. | 2009-01-15 |
20090018066 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING THE ACTIVITY OF A NOVEL TRIGLYCERIDE HYDROLASE - Use of an inhibitor or activator of the triglyceride hydrolyse activity of a protein comprising a polypeptide strand encoded by the DNA sequence according to SEQ No. 1 for the preparation of a pharmaceutical composition for the treatment of medical disorders where it is desirable to modulate the activity of a protein encoded by the DNA sequence according to SEQ No. 1. | 2009-01-15 |
20090018067 | REGULATORY T CELL EPITOPES, COMPOSITIONS AND USES THEREOF - The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention. | 2009-01-15 |
20090018068 | G-protein coupled receptors - The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host, cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC. | 2009-01-15 |
20090018069 | Methods and Compositions Related to Mutant Kunitz Domain I of Tfpi-2 - Disclosed are methods and compositions relating to plasmin inhibition. | 2009-01-15 |
20090018070 | Fsh Mutants - FSH mutants with increased glycosylation and longer half-lives are described. The use of FSH mutants for inducing folliculogenesis in human patients is also described. | 2009-01-15 |
20090018071 | EPIDIDYMIS-SPECIFIC RECEPTOR PROTEIN - The present invention relates to a novel transmembrane receptor protein which is specific to the mammalian epididymis, DNA sequences which code for the protein and specific ligands and to the use thereof for the preparation of agents for diagnosis of male infertility and for controlling maturation of spermatozoa. | 2009-01-15 |
20090018072 | HIGH PROTEIN SUPPLEMENT - The present disclosure relates to high protein dietary supplements for treating various symptoms and diseases associated with protein deficiency including weight gain, obesity, catabolic diseases, fibromyalgia, anxiety reactions, posttraumatic stress and chronic fatigue syndrome. Embodiments of dietary supplements comprise combinations of proteins, essential and semi-essential amino acids including L-Lysine, L-Arginine, and/or L-Histidine. | 2009-01-15 |
20090018073 | Methods for treating muscle diseases and disorders - The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185 | 2009-01-15 |
20090018074 | Peptides for Inhibiting Insects - The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed to target insects together with one or more insecticidal proteins, preferably (but not limited to) B.t. Cry proteins. When used in this manner, the peptide fragment can not only enhance the apparent toxin activity of the Cry protein against the insect species that was the source of the receptor but also against other insect species. Preferably, the cadherin is a | 2009-01-15 |
20090018075 | Peptides in Inhibiting Insects - The subject invention pertains to the use of peptide fragments of cadherins (including cadherin-like proteins). The subject invention includes a cell (and use thereof) comprising a polynucleotide that expresses the peptide fragment. The subject invention includes methods of feeding the peptides to insects. In preferred embodiments, the peptides are fed to target insects together with one or more insecticidal proteins, preferably (but not limited to) B.t. Cry proteins. When used in this manner, the peptide fragment can not only enhance the apparent toxin activity of the Cry protein against the insect species that was the source of the receptor but also against other insect species. Preferably, the cadherin is a | 2009-01-15 |
20090018076 | Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2009-01-15 |
20090018077 | Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 2009-01-15 |
20090018078 | Apoptosis-Modulating Protein Therapy for Proliferative Disorders and Nanoparticles Containing the Same - Protein containing nanoparticles and methods of use thereof for the treatment of proliferative disorders are disclosed. | 2009-01-15 |
20090018079 | OPTIMIZED DNA AND PROTEIN SEQUENCE OF AN ANTIBODY TO IMPROVE QUALITY AND YIELD OF BACTERIALLY EXPRESSED ANTIBODY FUSION PROTEINS - Object matter of the invention is an optimized DNA sequence encoding the scFv(FRP5) antibody fragment. This novel sequence prevents the generation of the undesired by-product in the context of an scFv(FRP5)-ETA fusion protein, and possibly also other bacterially expressed scFv(FRP5)-containing fusion proteins. The DNA sequence of the scFv(FRP5) domain of scFv(FRP5)-ETA was modified by exchanging a distinct codon, thereby preventing an otherwise possible internal start of protein translation. | 2009-01-15 |
20090018080 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2009-01-15 |
20090018081 | ACTIVATABLE CLOSTRIDIAL TOXINS - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 2009-01-15 |
20090018082 | Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma - The invention relates to the use of Factor VIIa or a Factor VIIa equivalent for the manufacture of a medicament for treatment of trauma. | 2009-01-15 |
20090018083 | Methods and compositions for inhibition of bcl6 repression - Provided are peptides or mimetics that block corepressor binding to a BCL6 lateral groove. Also provided are methods of blocking corepressor binding to the BCL6 lateral groove. Additionally, methods of inhibiting BCL6 repression in a mammalian, cell, and methods of treating a mammal with cancer are provided. | 2009-01-15 |
20090018084 | METHODS OF RESTORING COGNITIVE ABILITY USING NON-PEPTIDIC COMPOUNDS - Disclosed are methods of enhancing cognitive impairment in a patient wherein the cognitive impairment is due to ADDL neurotoxicity. The methods employ non-peptidic compounds having a molecular weight of less than 1000 and which can antagonize against formation of neurotoxic ADDLs from Aβ | 2009-01-15 |
20090018086 | Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus - Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit. | 2009-01-15 |
20090018087 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia. | 2009-01-15 |
20090018088 | TREATING CANCER WITH CARDIAC GLYCOSIDES - The invention provides methods to treat cancer with cardiac glycosides. | 2009-01-15 |
20090018089 | CRYSTALLINE FORMS OF MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY - the present invention relates to macrolide compounds endowed with antiinflammatory activity and more particularly relates to new stable crystalline forms of a macrolide derivative with antiinflammatory activity, processes for the preparation of such forms, pharmaceutical compositions containing them as active ingredient and the use of said crystalline forms for the treatment of inflammatory diseases. | 2009-01-15 |
20090018090 | PROCESS FOR PREPARATION OF ANHYDROUS AZITHROMYCIN - The present invention provides a stable form of azithromycin derivatives that act as antibiotics. These compounds are in anhydrous form and have increased stability over the hydrated forms. | 2009-01-15 |
20090018091 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use - The invention describes compositions and kits comprising at least one nitric oxide enhancing group antimicrobial compound, or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitric oxide enhancing antimicrobial compound, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating bacterial infections; (b) treating viral infections; (c) treating fungal infections; and (d) treating lesions. The antimicrobial compounds of the invention are preferably tobramycin, aztreonam, ciprofloxacin and doripenam. The nitric oxide enhancing antimicrobial compounds are substituted with at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group. The nitric oxide enhancing groups are nitroxides and/or heterocyclic nitric oxide donors. The heterocyclic nitric oxide donors are furoxans, sydnonimines, oxatriazole-5-ones and/or oxatriazole-5-imines. In one embodiment the methods of the invention are for the treatment of bacterial infections associated with pulmonary diseases such as cystic fibrosis and for treating | 2009-01-15 |
20090018092 | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids - The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher. | 2009-01-15 |
20090018093 | Nucleic Acid Ligands Specific to Immunoglobuline E and Their Use as Atopic Disease Therapeutics - The invention discloses aptamers capable of binding to Immunoglobulin E (“IgE”) useful as therapeutics in and diagnostics of atopic disease and/or other diseases or disorders in which IgE has been implicated. The invention further relates to materials and methods for the administration of aptamers capable of binding to IgE. | 2009-01-15 |
20090018094 | INHIBITION OF BRAIN ENZYMES INVOLVED IN CEREBRAL AMYLOID ANGIOPATHY AND MACULAR DEGENERATION - A method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal involves administering compositions containing siRNA to heme oxygenase-1 (HO-1) or heme oxygenase-2 (HO-2), a matrix metalloproteinase (MMP) inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient. | 2009-01-15 |
20090018095 | Fusion proteins of mycobacterium tuberculosis - The present invention relates to compositions and fusion proteins containing at least two | 2009-01-15 |
20090018096 | Methods For Regulating The Growth And/Or Survival Of Tumor Cells And Stem Cells By Modulating The Expression Or Function Of The Transcription Factor ATF5 - The present invention provides methods for regulating the growth and/or survival of tumor cells and stem cells by modulating the expression or function of ATF5. The present invention also provides methods for promoting or suppressing differentiation of stem/progenitor cells, for producing differentiated cells and for isolating/purifying differentiated cells, including neural cells. Also provided are differentiated cells, cell populations and transgenic animals comprising same and uses of same. The present invention further provides methods for treating nervous tissue degeneration and for identifying an agent for use in treating nervous tissue degeneration. Methods for promoting apoptosis in neoplastic cells and for treating or preventing tumors, and identifying agents for use in treating or preventing tumors are also provided by the present invention. The present invention further provides methods for identifying agents that inhibit ATF5, agents identified by these methods. Also provided are methods for diagnosing tumors, for assessing the efficacy of therapy to treat tumors and for assessing the prognosis of a subject who has a neural tumor. Finally, the present invention provides a kits for use in detecting and treating tumors. | 2009-01-15 |
20090018097 | MODIFICATION OF DOUBLE-STRANDED RIBONUCLEIC ACID MOLECULES - A double-stranded RNA (dsRNA) molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5′-methyl-pyrimidine and/or at least one 2′-O-methyl ribonucleotide, and a method of improving ribonuclease stability, reducing off-target effects of a double stranded siRNA molecule, or of reducing interferon responsiveness of a double stranded siRNA molecule using such dsRNA. | 2009-01-15 |
20090018098 | TARGETING THE ABSENCE: HOMOZYGOUS DNA DELETIONS AS SIGNPOSTS FOR CANCER THERAPY - The present application relates to methods and compositions for targeting a homozygous DNA deletion (HD) in cells. Methods, structures, vectors and compositions for activating a payload in cells having an HD are provided. In some embodiments, the method comprises administering, to a population of cells comprising at least one cell having an HD, a nucleic acid vector encoding two complementary protein fusion molecules and a payload such that the payload is selectively activated only in cells having a HD. HDs are attractive “negative” targets for cancer therapy because of their immutability and prevalence in cancer cells. Thus, in some embodiments methods of treating cancer by specifically delivering a payload, such as a toxin, to cancer cells comprising one or more particular HDs are provided. | 2009-01-15 |
20090018099 | PROTEIN PRODUCTION - The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport. | 2009-01-15 |
20090018100 | MATERIALS AND METHODS FOR TREATING OCULAR-RELATED DISORDERS - The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and the same or different nucleic acid sequence encoding a neurotrophic agent. The method also can comprise contacting an ocular cell with different expression vectors, each comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and/or a nucleic acid sequence encoding a neurotrophic agent. In addition, the present invention provides a viral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof. | 2009-01-15 |
20090018101 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES - S-Adenosyl- | 2009-01-15 |
20090018102 | Phamaceutical/cosmetic compositions comprising hyaluronic acid and treatment of dermatological conditions therewith - Pharmaceutical/cosmetic compositions containing a dermatologically effective amount of hyaluronic acid, at least one retinoid and/or salt and/or derivative thereof, at least one oligosaccharide and at least one inhibitor of hyaluronic acid degradation, formulated into a physiologically acceptable medium therefor, are useful for the treatment of wrinkles, fine lines, fibroblast depletions and scars. | 2009-01-15 |
20090018103 | Diaminoalkane Aspartic Protease Inhibitors - Diaminoalkanes of Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I. | 2009-01-15 |
20090018104 | Triarylcarboxylic Acid Derivative - Provided is a triarylcarboxylic acid derivative, or an isomer, a prodrug, a hydrate, a solvate, a polymorph, or a pharmaceutically acceptable salt thereof, represented by the following general formula (I): | 2009-01-15 |
20090018105 | Means and Methods for the Treatment and Prevention of Allergic Diseases - The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization. Preferred in this context are edelfosine and miltefosine. In a particularly preferred embodiment, the present invention relates to the use of miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma. | 2009-01-15 |
20090018106 | INTRAVENOUS FORMULATIONS OF PYRIDOXAL 5'- PHOSPHATE AND METHOD OF PREPARATION - The present invention provides a lyophilized formulation of pyridoxal 5′-phosphate and a method of making the same. The present invention also provides an injectable formulation of pyridoxal 5′-phosphate reconstituted from the lyophilized formulation. The present invention further provides uses of the lyophilized and injectable formulations. | 2009-01-15 |
20090018107 | NOVEL COMPOSITION TO INCREASE MUSCLE STRENGTH - The present invention relates to a composition for increasing testosterone physiological levels comprising a sufficient amount of at least two ketosteroid derivatives of testosterone metabolism in association with a liposomal carrier bound to a saliva-absorbing carrier for increasing testosterone physiological levels. | 2009-01-15 |
20090018108 | Treating skin hyperpigmentation with dermatological compositions comprising hydroquinone, fluocinolone acetonide and tretinoin - Hyperpigmentary skin disorders, notably those associated with psoriasis or eczema, are prevented/treated by administering to individuals in need of such treatment, thus effective amounts of medicaments containing a combination of fluocinolone acetonide, hydroquinone and tretinoin, formulated into a physiologically acceptable medium therefor. | 2009-01-15 |
20090018109 | COMBINATIONS OF STEROIDS AND METHYLXANTHINE COMPOUNDS - There is provided a medicament comprising a combination of a methylxanthine compound of formula I and a steroid of formula II and their use as pharmaceuticals, in particular for the treatment of inflammatory or obstructive airways diseases. | 2009-01-15 |
20090018110 | Haptoglobin genotyping for prognosis and treatment of chronic vasospasm following subarachnoid hemorrhage (SAH) - This invention relates to methods and systems for providing a prognosis to a subject on developing vasospasm as a results of hemorrhagic event, and compounds and compositions for treatment thereof. Specifically, the invention relates to the use of haptoglobin genotyping in the prognosis of the development of vasospasm following SAH, and antioxidants such as glutathione peroxidase mimetics for treatment. | 2009-01-15 |
20090018111 | Novel Antimicrobial Medicament - An antimicrobial combination medicament for injection comprising a β-lactam compound represented by the formula [1], | 2009-01-15 |
20090018112 | Compounds and Uses Thereof - This invention relates to novel compounds having the structural formula I below: | 2009-01-15 |
20090018113 | Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof - The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation. | 2009-01-15 |
20090018114 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to cannabinoid receptor ligands containing compounds of formula (I) | 2009-01-15 |
20090018115 | COMPOSITIONS OF AN ANTICONVULSANT AND AN ANTIPSYCHOTIC DRUG AND METHODS OF USING THE SAME FOR AFFECTING WEIGHT LOSS - Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant. | 2009-01-15 |
20090018116 | Therapeutic Compounds - Compounds of formula I or pharmaceutically acceptable salts thereof: | 2009-01-15 |
20090018117 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF - The disclosure relates to 2-carbamide-4-phenylthiazole derivatives having the following general formula (I): | 2009-01-15 |
20090018118 | HETEROCYCLIC COMPOUNDS - The invention is related to novel substituted diazaheterocycles useful as effective antihypercholesterolemic agents, methods of their preparation, and pharmaceutical compositions containing them. | 2009-01-15 |
20090018119 | USE OF N-DESMETHYLCLOZAPINE TO TREAT HUMAN NEUROPSYCHIATRIC DISEASE - Disclosed herein is a method to treat neuropsychiatric diseases including psychosis, affective disorders, dementia, neuropathic pain, and glaucoma. Treatment is carried out by administering a therapeutically effective amount of N-desmethylclozapine to a patient suffering from a neuropsychiatric disease. | 2009-01-15 |
20090018120 | AMIDINE DERIVATIVES AND THEIR APPLICATIONS AS A MEDICAMENT - The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen. | 2009-01-15 |
20090018121 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR RHEUMATOID ARTHRITIS - The present invention relates to a preventive and/or therapeutic agent for rheumatoid arthritis. The present invention provides a preventive and/or therapeutic agent for rheumatoid arthritis containing 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one and a COX2 inhibitor. | 2009-01-15 |
20090018122 | Aryloxy and Arylalkyleneoxy Substituted Imidazoquinolines - Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed. | 2009-01-15 |
20090018123 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation - The present invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines. | 2009-01-15 |
20090018124 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same - Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraines, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, strokes, bladder hypersensitivity, irritable bowel syndrome, respiratory disorders such as asthma, chronic obstructive pulmonary disease, etc., burns, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases. | 2009-01-15 |
20090018125 | Pharmaceutical Composition and Its Use - Polyunsaturated fatty acid (“PUFA”) or a pharmacologically acceptable salt or derivative thereof (such as EPA and/or DHA) is used in combination with at least one of an immunosuppressive agent or an antineoplastic agent, said agent(s) having at least one amino acid residue, or a pharmacologically acceptable salt or derivative thereof (such as methotrexate or cyclosporin) in the treatment of conditions involving acutely or chronically inadequate immune response. Specific conditions that may be treated include chronic inflammatory diseases (e.g. Crohn's disease and ulcerative colitis) and tumour diseases (e.g. bowel cancer and prostate cancer). One advantage of preferred embodiments of the invention is that bioavailability of immunosuppressive or antineoplastic agents is increased. | 2009-01-15 |
20090018126 | 4-Aminophenylmorpholinone Derivatives and Their Preparation - The invention relates to novel aminophenylmorpholinone derivates (I) | 2009-01-15 |
20090018127 | Ergoline Derivatives - Disclosed are ergoline derivatives, Formula (I), wherein either each of R | 2009-01-15 |
20090018128 | Compounds - The present invention relates to novel pyrrolopyrazine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. | 2009-01-15 |
20090018129 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME - The invention relates to substituted aminopyrazolopyridines according to the general formula (I): | 2009-01-15 |
20090018130 | Derivatives of 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxamide or 5-Aryl-1H-Pyrrolo [2, 3B] Pyridine-3-Carboxylic Acid - The present invention relates to new compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy. | 2009-01-15 |
20090018131 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives. | 2009-01-15 |
20090018132 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders - The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. | 2009-01-15 |
20090018133 | Novel Adamantane Derivatives - The invention provides compounds of formula (I), in which m, A, R | 2009-01-15 |
20090018134 | Compounds - 945 - A compound of formula (I) | 2009-01-15 |
20090018135 | Methods of treating bowel disorders - The present invention relates to methods for treating or preventing bowel disorders using calcimimetics. | 2009-01-15 |
20090018136 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DISEASE - The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes methods and compositions for treating such vascular disorders using compositions comprising BH4 and derivative thereof. Combination therapies of BH4 and other therapeutic regimens are contemplated. | 2009-01-15 |
20090018137 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES - Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions. | 2009-01-15 |
20090018138 | Treatment of CRTH2-mediated diseases and conditions - The present invention provides indole derivatives that antagonize prostaglandin D | 2009-01-15 |
20090018139 | Treatment of CRTH2-mediated diseases and conditions - The present invention provides indole derivatives that antagonize prostaglandin D | 2009-01-15 |
20090018140 | THIAZOLES AND OXAZOLES USEFUL AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2009-01-15 |
20090018141 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH - Provided herein are Compounds having the following structure: | 2009-01-15 |